Geneva based cleantech company Transmutex has completed its CHF 5.3 million Series A. This comes a couple months after its CHF 2.6 million seed financing round that completed in May. These financing rounds will allow Transmutex to
Kellerhals Carrard has acted as legal counsel to Stille, a medical device company, in acquiring all shares in Switzerland-based S&T, a manufacturer of microsurgical instruments, in exchange for CHF 6 million paid in cash
Advestra acted as legal counsel to One Equity Partners, a middle market private equity firm, in completing the acquisition of a 29 percent stake in Cicor Technologies (SIX Swiss Exchange: CICN), a Swiss provider of electronic
Givaudan, a Swiss manufacturer of flavours, fragrances and active cosmetic ingredients, has acquired a 25% stake in B. Kolormakeup & Skincare, an Italy-based company specialized in developing and producing end to end products in make-up and
Heuking Kühn Lüer Wojtek acted as legal counsel to Prose Group on the sale of its testing division, based in Germany and Switzerland, to Germany-based Tüv Süd, for an undisclosed consideration. &
Niederer Kraft Frey acted as legal counsel to Macquarie Group Limited on the offering of its CHF 320 million 0.395 percent bond due 2028. The bond is listed on SIX Swiss Exchange and represents Macquarie’s first group
Kuehne & Nagel International, a Switzerland-based provider of transport, logistics and supply chain management solutions, enters into a binding agreement to acquire 100% of the shares in Salmosped. The Oslo-based company is a Norwegian perishables freight
Switzerland based Dietrich Engineering Consultants has announced the acquisition of UK based Biotech and pharmaceutical system provider, Extract Technology, from Wabash National Corp, a U.S. listed trailer manufacturing company. The acquisition included Extract Technology
Switzerland-based global private markets firm, Partners Group, has, on behalf of its clients, agreed to acquire Pharmathen, a Greece-based pharmaceutical company, from international U.S. based investment firm BC Partners. The transaction values Pharmathen at
Ermenegildo Zegna Group, the privately-held Italian fashion company, will go public on the New York Stock Exchange later this year by way of a merger with Investindustrial Acquisition Corp., a special purpose acquisition corporation – or
